Lung cancer data are meeting’s main attraction
nospam@example.com (Clear the Smoke) wrote an interesting post today on
Here’s a quick excerpt
The study, set for release Sunday, seeks to determine whether Erbitux, co-marketed by ImClone Systems and Bristol-Myers Squibb, prolongs the lives of patients with advancd nonsmall cell lung cancer. The drug is currently approved for colorectal, head and neck cancer.
Read the rest of this great post here